Drug Use Investigation On Zithromac (Azithromycin) In HIV Patients
Drug Use Investigation On Zithromac Tablets 600mg In HIV Patients (Post Marketing Commitment Plan)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
Patients need to be administered Zithromac Tablets 600mg in order to be enrolled in the surveillance.
Exclusion Criteria:
Patients not administered Zithromac Tablets 600mg.
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Retrospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Azithromycin
Patients taking Azithromycin.
|
Inhibition of onset: Perorally administer 1200mg of azithromycin (potency) once a week to adults. Treatment: Perorally administer 600mg of azithromycin (potency) once a day to adults.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants With the Frequency of Treatment Related Adverse Events.
Time Frame: 9 years(MAX)
|
Adverse events mean all unfavorable events that occur in participants after administration of Azithromycin, irrespective of causal relationship to Azithromycin (including clinically problematic abnormal changes in laboratory test values).
Treatment related Adverse Events were evaluated in company with the causal relationship to Azithromycin.
|
9 years(MAX)
|
|
Number of Unlisted Treatment Related Adverse Events in Japanese Package Insert.
Time Frame: 9 years(MAX)
|
Adverse events mean all unfavorable events that occur in participants after administration of Azithromycin, irrespective of causal relationship to Azithromycin (including clinically problematic abnormal changes in laboratory test values).
Number of Treatment Related Adverse Events were evaluated in company with the causal relationship to Azithromycin.
Unlisted treatment related adverse events were confirmed with listed adverse drug reaction in Japanese package insert.
|
9 years(MAX)
|
|
Risk Factors for the Frequency of Treatment Related Adverse Events -Age (Prophylaxis).
Time Frame: 9 years(MAX)
|
Number of participants with Treatment Related Adverse Events(TRAEs) of Azithromycin to determine whether <65 years or >=65 years is significant risk factor.
|
9 years(MAX)
|
|
Risk Factors for the Frequency of Treatment Related Adverse Events -Gender (Prophylaxis).
Time Frame: 9 years(MAX)
|
Number of participants with Treatment Related Adverse Events(TRAEs) of Azithromycin Tablets to determine whether male or female is significant risk factor.
|
9 years(MAX)
|
|
Risk Factors for the Frequency of Treatment Related Adverse Events -Concomitant Drugs (Prophylaxis).
Time Frame: 9 years(MAX)
|
Number of participants with Treatment Related Adverse Events(TRAEs) of Azithromycin Tablets to determine whether with or without concomitant drugs is significant risk factor.
|
9 years(MAX)
|
|
Risk Factors for the Frequency of Treatment Related Adverse Events -Renal Dysfunction (Prophylaxis).
Time Frame: 9 years(MAX)
|
Number of participants with Treatment Related Adverse Events(TRAEs) of Azithromycin to determine whether with or without renal dysfunction is significant risk factor.
|
9 years(MAX)
|
|
Risk Factors for the Frequency of Treatment Related Adverse Events -Allergies (Prophylaxis).
Time Frame: 9 years(MAX)
|
Number of participants with Treatment Related Adverse Events(TRAEs) of Azithromycin to determine whether with or without allergies is significant risk factor.
|
9 years(MAX)
|
|
Risk Factors for the Frequency of Treatment Related Adverse Events -Age (Treatment).
Time Frame: 9 years(MAX)
|
Number of participants with Treatment Related Adverse Events(TRAEs) of Azithromycin to determine whether <65 years or >=65 years is significant risk factor.
|
9 years(MAX)
|
|
Risk Factors for the Frequency of Treatment Related Adverse Events -Gender (Treatment).
Time Frame: 9 years(MAX)
|
Number of participants with Treatment Related Adverse Events(TRAEs) of Azithromycin Tablets to determine whether male or female is significant risk factor.
|
9 years(MAX)
|
|
Risk Factors for the Frequency of Treatment Related Adverse Events -Renal Dysfunction (Treatment).
Time Frame: 9 years(MAX)
|
Number of participants with Treatment Related Adverse Events(TRAEs) of Azithromycin to determine whether with or without renal dysfunction is significant risk factor.
|
9 years(MAX)
|
|
Risk Factors for the Frequency of Treatment Related Adverse Events -Allergies (Treatment).
Time Frame: 9 years(MAX)
|
Number of participants with Treatment Related Adverse Events(TRAEs) of Azithromycin to determine whether with or without allergies is significant risk factor.
|
9 years(MAX)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants That Responded to Azithromycin Treatment.
Time Frame: 9 years(MAX)
|
The physician performed efficacy evaluations at the end of the observation period (or the time of discontinuing administration), compared with the data before the start of administration of this drug, and entered the results.
|
9 years(MAX)
|
|
Number of Participants Prevented by Azithromycin Treatment.
Time Frame: 9 years(MAX)
|
The physician performed efficacy evaluations at the end of the observation period (or the time of discontinuing administration), compared with the data before the start of administration of this drug, and entered the results.
|
9 years(MAX)
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- HIV Infections
- Anti-Infective Agents
- Anti-Bacterial Agents
- Azithromycin
Other Study ID Numbers
Other Study ID Numbers
- A0661097
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.